Anisha Doshi
YOU?
Author Swipe
View article: The ABILHAND‐23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross‐Sectional Analysis With the Nine Hole Peg Test
The ABILHAND‐23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross‐Sectional Analysis With the Nine Hole Peg Test Open
Background People with progressive multiple sclerosis (pwPMS), who typically have established lower limb dysfunction, experience greater disability from upper limb dysfunction (ULD). The 9‐hole peg test (9HPT) is the primary clinical measu…
View article: Neurodevelopmental Disorders and L-carnosine: A Clinical Perspective
Neurodevelopmental Disorders and L-carnosine: A Clinical Perspective Open
View article: A45 Active Participation Versus Observation in High-Fidelity Simulation: A Comparative Study of Skill Retention and Clinical Performance in Medical Education
A45 Active Participation Versus Observation in High-Fidelity Simulation: A Comparative Study of Skill Retention and Clinical Performance in Medical Education Open
Introduction: High-Fidelity (Hi-Fi) Simulation is essential in medical education, offering realistic clinical training in safe environments. However, the intensive resource requirements of specialised equipment, dedicated simulation suites…
View article: A93 Evaluating AI-Generated Case-Based Learning as a Scalable Solution for Sustainable Medical Education
A93 Evaluating AI-Generated Case-Based Learning as a Scalable Solution for Sustainable Medical Education Open
Introduction: Case-based learning (CBL) is a widely used teaching method, promoting clinical reasoning and application of knowledge through structured scenarios (1). Developing high quality CBL materials requires significant expertise and …
View article: Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial Open
National Institute for Health and Care Research Health Technology Assessment Programme, UK Multiple Sclerosis Society, and the US National Multiple Sclerosis Society.
View article: Unsupervised Classification of Absorbing Aerosols with the SP2 via a Variational Autoencoder (VAE)
Unsupervised Classification of Absorbing Aerosols with the SP2 via a Variational Autoencoder (VAE) Open
The Single Particle Soot Photometer (SP2) detects refractory aerosol particle mass on a single-particle basis via laser-induced incandescence (L-II). While the SP2 has traditionally been used to quantify black carbon aerosol mass in the at…
View article: Executive Dysfunction and Disability in <scp>SPMS</scp>: Predictive Value of the Frontal Assessment Battery in the <scp>UCLH MS</scp>‐<scp>STAT2</scp> Cohort
Executive Dysfunction and Disability in <span>SPMS</span>: Predictive Value of the Frontal Assessment Battery in the <span>UCLH MS</span>‐<span>STAT2</span> Cohort Open
Introduction Cognitive impairment is common in secondary progressive multiple sclerosis (SPMS), with executive dysfunction disproportionately so. The frontal assessment battery (FAB) is a bedside test assessing executive function. This stu…
View article: Investigating the impact of different dichotomous definitions for cognitive impairment on functional connectivity in secondary progressive MS
Investigating the impact of different dichotomous definitions for cognitive impairment on functional connectivity in secondary progressive MS Open
View article: Neurofilament heavy chain in secondary progressive multiple sclerosis
Neurofilament heavy chain in secondary progressive multiple sclerosis Open
Background: Biomarkers are needed to track progression in MS trials. Neurofilament heavy chain (NfH) has been underutilized due to assay limitations. Objective: To investigate the added value of cerebrospinal fluid (CSF) NfH in secondary p…
View article: Vascular risk factors are associated with grey matter atrophy in secondary progressive multiple sclerosis
Vascular risk factors are associated with grey matter atrophy in secondary progressive multiple sclerosis Open
Background Comorbidities including vascular risk factors can be associated with whole and regional brain atrophy in multiple sclerosis (MS). This has been examined in mixed MS cohorts in prospective or observational studies; however, the a…
View article: Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial
Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial Open
Background Optical coherence tomography (OCT) inner retinal metrics reflect neurodegeneration in multiple sclerosis (MS). We explored OCT measures as biomarkers of disease severity in secondary progressive MS (SPMS). Methods We investigate…
View article: Investigating the relationship between thalamic iron concentration and disease severity in secondary progressive multiple sclerosis using quantitative susceptibility mapping: Cross-sectional analysis from the MS-STAT2 randomised controlled trial
Investigating the relationship between thalamic iron concentration and disease severity in secondary progressive multiple sclerosis using quantitative susceptibility mapping: Cross-sectional analysis from the MS-STAT2 randomised controlled trial Open
View article: Brain reserve and physical disability in secondary progressive multiple sclerosis
Brain reserve and physical disability in secondary progressive multiple sclerosis Open
Background The brain reserve hypothesis posits that larger maximal lifetime brain growth (MLBG) may confer protection against physical disability in multiple sclerosis (MS). Larger MLBG as a proxy for brain reserve, has been associated wit…
View article: Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK Open
Introduction There remains a high unmet need for disease-modifying therapies that can impact disability progression in secondary progressive multiple sclerosis (SPMS). Following positive results of the phase 2 MS-STAT study, the MS-STAT2 p…
View article: A Deep Learning Pipeline for Drought Assessment using Spatial Satellite Images and Vision Transformers
A Deep Learning Pipeline for Drought Assessment using Spatial Satellite Images and Vision Transformers Open
700 million people are in danger of being displaced due to inept drought prediction and prevention systems. Current research on drought assessment focuses solely on factors such as soil moisture and rainfall, which require painstaking meas…
View article: RETRACTED: Real-Time Coal Emissions Monitoring System Using Geospatial Satellite Images and Deep Neural Networks
RETRACTED: Real-Time Coal Emissions Monitoring System Using Geospatial Satellite Images and Deep Neural Networks Open
View article: Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective Treatments
Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective Treatments Open
Background 1 H‐magnetic resonance spectroscopy ( 1 H‐MRS) may provide a direct index for the testing of medicines for neuroprotection and drug mechanisms in multiple sclerosis (MS) through measures of total N ‐acetyl‐aspartate (tNAA), tota…
View article: Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross‐sectional analysis from the <scp>MS‐STAT2</scp> randomized controlled trial
Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross‐sectional analysis from the <span>MS‐STAT2</span> randomized controlled trial Open
Background and purpose There is increasing evidence that cardiovascular risk (CVR) contributes to disability progression in multiple sclerosis (MS). CVR is particularly prevalent in secondary progressive MS (SPMS) and can be quantified thr…
View article: Optimising recruitment in clinical trials for progressive multiple sclerosis: observational analysis from the MS-SMART and MS-STAT2 randomised controlled trials
Optimising recruitment in clinical trials for progressive multiple sclerosis: observational analysis from the MS-SMART and MS-STAT2 randomised controlled trials Open
Background Slower than planned recruitment is a major factor contributing to the delay or failure of randomised controlled trials to report on time. There is a limited evidence base regarding the optimisation of recruitment strategies. Her…
View article: Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial
Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: Analysis from the MS-STAT randomised controlled trial Open
Background: Cognitive impairment affects 50%–75% of people with secondary progressive multiple sclerosis (PwSPMS). Improving our ability to predict cognitive decline may facilitate earlier intervention. Objective: The main aim of this stud…
View article: 007 The MS-STAT2 trial in secondary progressive MS – study design and update
007 The MS-STAT2 trial in secondary progressive MS – study design and update Open
The MS-STAT2 study is a Phase III, 3 year multi-centre, randomised, placebo-controlled trial assessing the efficacy of 80mg simvastatin vs. placebo in secondary progressive multiple sclerosis (SPMS). Building upon the promising results of …
View article: Additional file 1 of Optimising recruitment in clinical trials for progressive multiple sclerosis: observational analysis from the MS-SMART and MS-STAT2 randomised controlled trials
Additional file 1 of Optimising recruitment in clinical trials for progressive multiple sclerosis: observational analysis from the MS-SMART and MS-STAT2 randomised controlled trials Open
Additional file 1. Prescreen Checklist. Investigator groups.
View article: A systematic review of resting state functional MRI connectivity changes and cognitive impairment in multiple sclerosis
A systematic review of resting state functional MRI connectivity changes and cognitive impairment in multiple sclerosis Open
Cognitive impairment is common in multiple sclerosis (MS) and resting state functional MRI (rs-fMRI) functional connectivity (FC) is increasingly used to study its pathophysiology. However, results remain difficult to interpret, showing bo…
View article: NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study
NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study Open
This study suggests that metabolic markers of neuroaxonal integrity and astrogliosis in normal-appearing WM and membrane turnover in GM may act as markers of disability in secondary-progressive MS.
View article: MS-SMART study: systematic sampling bias concerns – Authors' reply
MS-SMART study: systematic sampling bias concerns – Authors' reply Open
View article: Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT
Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT Open
Background Neuroprotective drugs are needed to slow or prevent neurodegeneration and disability accrual in secondary progressive multiple sclerosis. Amiloride, fluoxetine and riluzole are repurposed drugs with potential neuroprotective eff…
View article: Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial Open
View article: Sex effects across the lifespan in women with multiple sclerosis
Sex effects across the lifespan in women with multiple sclerosis Open
Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating central nervous system disorder that is more common in women, with onset often during reproductive years. The female:male sex ratio of MS rose in several regions over the …
View article: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis Open
Introduction The major unmet need in multiple sclerosis (MS) is for neuroprotective therapies that can slow (or ideally stop) the rate of disease progression. The UK MS Society Clinical Trials Network (CTN) was initiated in 2007 with the p…
View article: Multiple Sclerosis Impact Scale and brain volume are independent predictors of cognitive impairment in Secondary Progressive Multiple Sclerosis
Multiple Sclerosis Impact Scale and brain volume are independent predictors of cognitive impairment in Secondary Progressive Multiple Sclerosis Open